What this is
- How it works
- How it works isn't classified yet
- Tested for
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
- Main trialPhase 1
- “This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.”In the company’s words, NCT04969835 on ClinicalTrials.gov
Other drugs for Salivary Gland Tumor
- GotistobartOncoC4 · BioNTech · Phase 1/2
- ZanidatamabJazz Pharmaceuticals · Phase 2
- LCB84LigaChem Biosciences, Inc. · Phase 1/2
- PembrolizumabMerck & Co. · Phase 2
- EntrectinibRoche · Phase 1/2
- IvonescimabAkeso · Summit Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 7 Aug 2026 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026